Phase IIa examination of the effect of oral dosing of NV-52 on surrogate markers of inflammatory bowel disease (IBD) in patients with stable disease but with a consistent abnormality in one or more surrogate marker.

This study investigates phase IIa examination of the effect of oral dosing of NV-52 on surrogate markers of inflammatory bowel disease (IBD) in patients with stable disease but with a consistent abnormality in one or more surrogate marker.. It is open to aged 18 and older. To join, participants should meet criteria including: healthy, (without clinically significant impairment in cardiac, liver or renal function, central nervous system, pulm.... People who have patients whose symptoms deteriorate to the point of acute relapse (CDAI > 200, UCAI > 4).